For sometime on this thread we have been considering the possible second indication that we might peruse. The NASA/Space angle is certainly interesting but I struggle to see how it could be a commercial proposition. I was digging around in some of the latest academic research for Exenatide and I came across this.
It seems to me this is an excellent area for us to explore, it is a large market with little available treatment and no prophylactic options. It fits neatly within Alex Sinclair's area of clinical experience and expertise. Clearly at a board level Megan Baldwin (CEO/MD of Opthea) and Tom Duthy (Advisor with Ellex Laser/Nova Eye) and chairman Jason Loveridge (Genable) also have significant experience in related adjacent areas.
I am putting my money on an announcement in the area at some point next year.
IXC Price at posting:
70.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)